43152-60-9 Usage
General Description
1-(2-Indanyl)pyrrolidine is a chemical compound with the molecular formula C13H17N. It is a heterocyclic compound consisting of a pyrrolidine ring attached to an indane moiety. 1-(2-Indanyl)pyrrolidine has been studied for its potential pharmaceutical applications, including its role as a dopamine agonist. It has also been investigated for its potential use in the development of novel psychoactive substances. Additionally, 1-(2-Indanyl)pyrrolidine has been evaluated for its chemical and physical properties, including its solubility and stability, in order to better understand its potential uses and applications in various fields such as medicine, chemistry, and material science.
Check Digit Verification of cas no
The CAS Registry Mumber 43152-60-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,3,1,5 and 2 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 43152-60:
(7*4)+(6*3)+(5*1)+(4*5)+(3*2)+(2*6)+(1*0)=89
89 % 10 = 9
So 43152-60-9 is a valid CAS Registry Number.
InChI:InChI=1/C13H17N/c1-2-6-12-10-13(9-11(12)5-1)14-7-3-4-8-14/h1-2,5-6,13H,3-4,7-10H2
43152-60-9Relevant articles and documents
Asymmetric Pd-Catalyzed Alkene Carboamination Reactions for the Synthesis of 2-Aminoindane Derivatives
White, Derick R.,Hutt, Johnathon T.,Wolfe, John P.
, p. 11246 - 11249 (2015/09/21)
A new type of Pd-catalyzed alkene carboamination reaction that provides direct access to enantioenriched 2-aminoindanes from 2-allylphenyltriflate derivatives and aliphatic amines is described. A catalyst generated in situ from Pd(OAc)2 and (S)-tert-butylPHOX provides the functionalized carbocycles in good yield with up to >99:1 er. The transformations occur via a key anti-aminopalladation that involves intermolecular attack of an amine nucleophile on an arylpalladium alkene complex.
PYRIDOPYRIMIDINONE INHIBITORS OF KINASES
-
Paragraph 0615, (2013/09/12)
The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1, R2, R3, R4, and B are defined in the description. The present invention relates also to compositions cont
